Author Archives: admin


Stem Cell Clinic > Articles by: admin

UCLA and UCI Awarded $8M Grant to Launch Collaborative Stem Cell Clinic "Center of Excellence"

By Uncategorized

Contact Information

Available for logged-in reporters only

Newswise In a first-of-its-kind collaboration, the University of California, Los Angeles, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and University of California, Irvine Sue & Bill Gross Stem Cell Research Center received a five year $8M grant from the California Institute of Regenerative Medicine (CIRM), the states stem cell agency, to establish a CIRM Alpha Stem Cell Clinic center of excellence to conduct clinical trials for investigational stem cell therapies and provide critical resources and expertise in clinical research.

The $8M grant was one of three awarded today by CIRM as part of the CIRM Alpha Stem Cell Clinics (CASC) Network Initiative. The joint UCLA/UCI award under the direction of Dr. John Adams, a member of the UCLA Broad Stem Cell Research Center and professor in the department of orthopaedic surgery, will accelerate the implementation of clinical trials and delivery of stem cell therapies by providing world-class, state-of-the-art infrastructure to support clinical research.

CIRM grant reviewers lauded the UCLA/UCI Consortiums impressive and multidimensional team of experienced personnel that will expand access to patients, attracting national and international clinical trials and accelerating future trials in the pipeline.

The initial stem cell trials supported by the UCLA/UCI Alpha Stem Cell Clinic will be two UCLA projects using blood forming stem cells. The first trial will test a stem cell-based gene therapy for patients with bubble baby disease, also called severe combined immune deficiency (SCID), in which babies are born without an immune system. Under the direction of Dr. Donald Kohn, the clinical trial will use the babys own stem cells with an inserted gene modification to correct the defect and promote the creation of an immune system. The second clinical trial, under the direction of Dr. Antoni Ribas, will use patients own genetically modified blood-forming stem cells to engineer and promote an immune response to melanoma and sarcomas.

This CIRM Alpha Stem Cell Clinic grant is an important acknowledgement of our cutting-edge research and will help us to advance the design, testing and delivery of effective and safe stem cell-based therapies, said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center. The implementation of a standard of excellence in clinical research will improve healthcare and the lives of patients far beyond the longevity of individual trials.

Operating as part of the larger state-wide CIRM supported network, Alpha Stem Cell Clinics provide critical operational support to conduct clinical trials, with focused resources and expertise in stem cell-based clinical research including clinical operations support and patient care coordination personnel.

UCI has established a strong preclinical stem cell research program, and its vital to move ahead to the clinical testing phase, said Sidney Golub, director of UCIs Sue & Bill Gross Stem Cell Research Center. To advance treatments in this field, we all have to work together, and thats what the UCLA-UCI Alpha Stem Cell Clinic program represents.

About the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research

See the original post here:
UCLA and UCI Awarded $8M Grant to Launch Collaborative Stem Cell Clinic "Center of Excellence"

UCSD, other stem cell clinics get millions

By Stem Cell Treatment

UCSD oncologist/researcher Catriona Jamieson is principal investigator for the university's $8 million stem cell grant.

To speed up the quest to bring stem cell therapies to patients, a state agency on Thursday granted $8 million each to three academic medical centers pursuing "translational" work -- UC San Diego, UC Los Angeles and City of Hope in Duarte.

The California Institute for Regenerative Medicine voted 10-1 to fund the "alpha" stem cell clinics, which are intended to bring stem cell treatments to the public.

UC San Diego's proposal supports two stem cell-based clinical trials, both already underway. Catriona Jamieson, an oncologist at the university, is the principal investigator for the grant.

One, a treatment for Type 1 diabetes, was developed by San Diego's ViaCyte. The other, for spinal cord injuries, was developed by Geron of Menlo Park. Geron dropped the trial, but it was picked up by Neuralstem of Germantown, Md. In October, UCSD treated the first patient in the revived trial at the university's Sanford Stem Cell Clinical Center.

The stem cell agency, commonly called CIRM, has focused heavily on basic research since its founding by California voters in 2004. But in recent years, the public has become more anxious to see the fruits of $3 billion in bond money given to the agency reach patients. The "alpha" clinics funded Thursday are part of that effort.

Early optimism that treatments would be quickly available was disappointed, mainly because issues of safety had to be resolved first. Therapies that actually place cells in the body posed new risks, because as living things, cells grow and can migrate. Embryonic stem cells can form tumors. Viacyte and Neuralstem grow replacement tissues from embryonic stem cells, so they needed to show that no unconverted cells would accidentally be introduced into the patient.

Skepticism has also grown over the ethics of CIRM officials, mainly regarding conflicts of interests. Many CIRM board members are chosen from institutions that get funded -- a feature written into the agency by Prop. 71. CIRM has adopted reforms to limit board members from voting in matters where they have conflicts. But CIRM's previous president, Alan Trounson, caused more controversy when he joined the board of CIRM-funded Stemcells Inc, just one week after departing the agency.

CIRM President Randy Mills, who replaced Trounson earlier this year, has tried to quell the controversy with new standards to prevent officials like Trounson from appearing to cash in on their agency role. And he has worked with the governing board to rethink how the agency's remaining funds can be best spent.

CIRM has invested heavily in San Diego stem cell programs, most notably contributing $43 million to a $127 million "collaboratory" building across from the Salk Institute in La Jolla. The Sanford Consortium, as it's called, brings together researchers from five institutions: UCSD, the Salk Institute, The Scripps Research Institute, the Sanford-Burnham Medical Research Institute and the La Jolla Institute for Allergy & Immunology.

Follow this link:
UCSD, other stem cell clinics get millions

Silencing the Speech Gene FOXP2 Causes Breast Cancer Cells to Metastasize

By Stem Cell Medical Center

Contact Information

Available for logged-in reporters only

Newswise BOSTON It is an intricate network of activity that enables breast cancer cells to move from the primary breast tumor and set up new growths in other parts of the body, a process known as metastasis.

Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has identified an unexpected link between a transcription factor known to regulate speech and language development and metastatic colonization of breast cancer.

Currently described online in Cell Stem Cell, the new findings demonstrate that, when silenced, the FOXP2 transcription factor, otherwise known as the speech gene, endows breast cancer cells with a number of malignant traits and properties that enable them to survive and thrive.

We have identified a previously undescribed function for the transcription factor FOXP2 in breast cancer, explains senior author Antoine Karnoub, PhD, an investigator in the Department of Pathology at BIDMC and Assistant Professor of Pathology at Harvard Medical School. We have found that depressed FOXP2 [a member of the forkhead family of transcriptional regulators] and elevated levels of its upstream inhibitor microRNA 199a are prominent features of clinically advanced breast cancers that associate with poor patient survival.

Karnoubs lab investigates the roles that mesenchymal stem cells (MSCs) play in the development and metastasis of breast cancer. MSCs are adult progenitor cells that function as the bodys early responders, poised to take action to help repair damaged tissues, jumping from their niches in the bone, for example, into the blood, migrating to areas of inflammation, and orchestrating the bodys reactions during wound healing. Previous work by Karnoub revealed that MSCs respond to breast tumors akin to the way they react to a wound or infection and that these cells participate in the formation of the breast tumor stroma, the supporting network of cells and their secretions that exist in the microenvironment of cancer cells.

We think that by direct actions on the cancer cells and by manipulating other cells in the microenvironment, MSCsend up providing cancer cells with better abilities to survive and a safe haven in which to thrive, says Karnoub. Despite expanding knowledge of the role of MSCs to breast malignancy, the underlying molecular responses of breast cancer cells to MSC influences has not been fully delineated. In this new paper, the investigators set out to specifically identify the role that microRNAs were playing in the process.

miRNAs are short noncoding RNAs that play critical functions in cancer pathogenesis,. An expanding body of evidence has documented miRNA deregulation in multiple aspects of tumor development, including invasion and metastasis, says Karnoub. The induction by MSCs of one such miRNA, miR199a, facilitated the acquisition of malignant properties by the cancer cells, including cancer stem cell and metastatic traits. (Cancer stem cells are thought to be the most virulent cells that lie within the core of most tumors, and are believed to be responsible for the resurgence of tumors following chemotherapy treatment.)

After we found that miRNA-199a instigated in the cancer cells by MSCs was indeed promoting these cancer stem cells phenotypes and was facilitating cancer metastasis, we probed the mechanistic details of miR-199as actions, explains Karnoub. miRNAs function predominantly by suppressing target mRNA expression, and we analyzed an overwhelming majority of the published targets that have been associated with these miRNAs, but none was repressed in our systems. We then made a screen and serendipitously fished out a gene called FOXP2. At that time, he adds, basically nothing was known about this protein in relation to breast cancer.

See original here:
Silencing the Speech Gene FOXP2 Causes Breast Cancer Cells to Metastasize

NYSCF Research Institute announces largest-ever stem cell repository

By Stem Cell Medical Center

14 hours ago

The New York Stem Cell Foundation (NYSCF) Research Institute, through the launch of its repository in 2015, will provide for the first time the largest-ever number of stem cell lines available to the scientific research community. Initially, over 600 induced pluripotent stem (iPS) cell lines and 1,000 cultured fibroblasts from over 1,000 unique human subjects will be made available, with an increasing number available in the first year. To collect these samples, NYSCF set up a rigorous human subjects system that protects patients and allows for the safe and anonymous collection of samples from people interested in participating in research.

A pilot of over 200 of NYSCF's iPS cell lines is already searchable on an online database. The pilot includes panels of iPS cell lines generated from donors affected by specific diseases such as type 1 diabetes, Parkinson's disease, and multiple sclerosis, as well as a diversity panel of presumed healthy donors from a wide range of genetic backgrounds representing the United States Census. These panels, curated to provide ideal initial cohorts for studying each area, include subjects ranging in age of disease onset, and are gender matched. Other panels that will be available in 2015 include Alzheimer's disease, schizophrenia, Juvenile Batten disease, and Charcot-Marie-Tooth disease.

"NYSCF's mission is to develop new treatments for patients. Building the necessary infrastructure and making resources available to scientists around the world to further everyone's research are critical steps in accomplishing this goal," said Susan L. Solomon, CEO of The New York Stem Cell Foundation.

NYSCF has developed the technology needed to create a large collection of stem cell lines representing the world's population. This platform, known as the NYSCF Global Stem Cell ArrayTM, is an automated robotic system for stem cell production and is capable of generating 200 iPS cell lines a month from patients with various diseases and conditions and from all genetic backgrounds. The NYSCF Global Stem Cell ArrayTM is also used for stem cell differentiation and drug screening.

Currently available in the online database that was developed in collaboration with eagle-i Network, of the Harvard Catalyst, is a pilot set of approximately 200 iPS cell lines and related information about the patients. This open source, open access resource discovery platform makes the cell lines and related information available to the public on a user-friendly, web-based, searchable system. This is one example of NYSCF's efforts to reduce duplicative research and enable even broader collaborative research efforts via data sharing and analysis. NYSCF continues to play a key role in connecting the dots between patients, scientists, funders, and outside researchers that all need access to biological samples.

"The NYSCF repository will be a critical complement to other existing efforts which are limited in their ability to distribute on a global scale. I believe that this NYSCF effort wholly supported by philanthropy will help accelerate the use of iPS cell based technology," said Dr. Mahendra Rao, NYSCF Vice President of Regenerative Medicine.

To develop these resources, NYSCF has partnered with over 50 disease foundations, academic institutions, pharmaceutical companies, and government entities, including the Parkinson's Progression Markers Initiative (PPMI), PersonalGenomes.org, the Beyond Batten Disease Foundation, among several others. NYSCF also participates in and drives a number of large-scale multi stakeholder initiatives including government and international efforts. One such example is the Cure Alzheimer's Fund Stem Cell Consortium, a group consisting of six institutions, including NYSCF, directly investigating, for the first time, brain cells in petri dishes from individual patients who have the common sporadic form of Alzheimer's disease.

"We are entering this next important phase of using stem cells to understand disease and discover new drugs. Having collaborated with NYSCF extensively over the last five years on the automation of stem cell production and differentiation, it's really an exciting moment to see these new technologies that NYSCF has developed now being made available to the entire academic and commercial research communities," said Dr. Kevin Eggan, Professor of Stem Cell and Regenerative Biology at Harvard University and Principal Investigator of the Harvard Stem Cell Institute.

NYSCF's unique technological resources have resulted in partnerships with companies to develop both stem cell lines and also collaborative research programs. Over the past year, NYSCF has established collaborations with four pharmaceutical companies to accelerate the translation of basic scientific discoveries into the clinic. Federal and state governments are also working with NYSCF to further stem cell research in the pursuit of cures. In 2013, NYSCF partnered with the National Institutes of Health (NIH) Undiagnosed Disease Program (UDP) to generate stem cell lines from 100 patients in the UDP and also collaborate with UDP researchers to better understand and potentially treat select rare diseases.

Read more from the original source:
NYSCF Research Institute announces largest-ever stem cell repository

The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository

By Uncategorized

PUBLIC RELEASE DATE:

22-Oct-2014

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf

NEW YORK, NY (October 22, 2014) The New York Stem Cell Foundation (NYSCF) Research Institute, through the launch of its repository in 2015, will provide for the first time the largest-ever number of stem cell lines available to the scientific research community. Initially, over 600 induced pluripotent stem (iPS) cell lines and 1,000 cultured fibroblasts from over 1,000 unique human subjects will be made available, with an increasing number available in the first year. To collect these samples, NYSCF set up a rigorous human subjects system that protects patients and allows for the safe and anonymous collection of samples from people interested in participating in research.

A pilot of over 200 of NYSCF's iPS cell lines is already searchable on an online database. The pilot includes panels of iPS cell lines generated from donors affected by specific diseases such as type 1 diabetes, Parkinson's disease, and multiple sclerosis, as well as a diversity panel of presumed healthy donors from a wide range of genetic backgrounds representing the United States Census. These panels, curated to provide ideal initial cohorts for studying each area, include subjects ranging in age of disease onset, and are gender matched. Other panels that will be available in 2015 include Alzheimer's disease, schizophrenia, Juvenile Batten disease, and Charcot-Marie-Tooth disease.

"NYSCF's mission is to develop new treatments for patients. Building the necessary infrastructure and making resources available to scientists around the world to further everyone's research are critical steps in accomplishing this goal," said Susan L. Solomon, CEO of The New York Stem Cell Foundation.

NYSCF has developed the technology needed to create a large collection of stem cell lines representing the world's population. This platform, known as the NYSCF Global Stem Cell ArrayTM, is an automated robotic system for stem cell production and is capable of generating 200 iPS cell lines a month from patients with various diseases and conditions and from all genetic backgrounds. The NYSCF Global Stem Cell ArrayTM is also used for stem cell differentiation and drug screening.

Currently available in the online database that was developed in collaboration with eagle-i Network, of the Harvard Catalyst, is a pilot set of approximately 200 iPS cell lines and related information about the patients. This open source, open access resource discovery platform makes the cell lines and related information available to the public on a user-friendly, web-based, searchable system. This is one example of NYSCF's efforts to reduce duplicative research and enable even broader collaborative research efforts via data sharing and analysis. NYSCF continues to play a key role in connecting the dots between patients, scientists, funders, and outside researchers that all need access to biological samples.

"The NYSCF repository will be a critical complement to other existing efforts which are limited in their ability to distribute on a global scale. I believe that this NYSCF effort wholly supported by philanthropy will help accelerate the use of iPS cell based technology," said Dr. Mahendra Rao, NYSCF Vice President of Regenerative Medicine.

To develop these resources, NYSCF has partnered with over 50 disease foundations, academic institutions, pharmaceutical companies, and government entities, including the Parkinson's Progression Markers Initiative (PPMI), PersonalGenomes.org, the Beyond Batten Disease Foundation, among several others. NYSCF also participates in and drives a number of large-scale multi stakeholder initiatives including government and international efforts. One such example is the Cure Alzheimer's Fund Stem Cell Consortium, a group consisting of six institutions, including NYSCF, directly investigating, for the first time, brain cells in petri dishes from individual patients who have the common sporadic form of Alzheimer's disease.

Continued here:
The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository

Human Skin Cells Reprogrammed Directly Into Brain Cells

By Uncategorized

Contact Information

Available for logged-in reporters only

Newswise Scientists have described a way to convert human skin cells directly into a specific type of brain cell affected by Huntingtons disease, an ultimately fatal neurodegenerative disorder. Unlike other techniques that turn one cell type into another, this new process does not pass through a stem cell phase, avoiding the production of multiple cell types, the studys authors report.

The researchers, at Washington University School of Medicine in St. Louis, demonstrated that these converted cells survived at least six months after injection into the brains of mice and behaved similarly to native cells in the brain.

Not only did these transplanted cells survive in the mouse brain, they showed functional properties similar to those of native cells, said senior author Andrew S. Yoo, PhD, assistant professor of developmental biology. These cells are known to extend projections into certain brain regions. And we found the human transplanted cells also connected to these distant targets in the mouse brain. Thats a landmark point about this paper.

The work appears Oct. 22 in the journal Neuron.

The investigators produced a specific type of brain cell called medium spiny neurons, which are important for controlling movement. They are the primary cells affected in Huntingtons disease, an inherited genetic disorder that causes involuntary muscle movements and cognitive decline usually beginning in middle-adulthood. Patients with the condition live about 20 years following the onset of symptoms, which steadily worsen over time.

The research involved adult human skin cells, rather than more commonly studied mouse cells or even human cells at an earlier stage of development. In regard to potential future therapies, the ability to convert adult human cells presents the possibility of using a patients own skin cells, which are easily accessible and wont be rejected by the immune system.

To reprogram these cells, Yoo and his colleagues put the skin cells in an environment that closely mimics the environment of brain cells. They knew from past work that exposure to two small molecules of RNA, a close chemical cousin of DNA, could turn skin cells into a mix of different types of neurons.

In a skin cell, the DNA instructions for how to be a brain cell, or any other type of cell, is neatly packed away, unused. In past research published in Nature, Yoo and his colleagues showed that exposure to two microRNAs called miR-9 and miR-124 altered the machinery that governs packaging of DNA. Though the investigators still are unraveling the details of this complex process, these microRNAs appear to be opening up the tightly packaged sections of DNA important for brain cells, allowing expression of genes governing development and function of neurons.

Read the original post:
Human Skin Cells Reprogrammed Directly Into Brain Cells

University Of Pennsylvania's T-Cell Therapy Shows Promising Results

By Uncategorized

By C. Rajan, contributing writer

The University of Pennsylvania has announced promising results of its novel chimeric antigen receptor (CAR) therapy for cancer.

In the study involving 25 children and five adults with end-stage acute lymphoblastic leukemia (ALL), there was an impressive 90 percent response rate with complete remission.

Twenty-seven of the 30 patients went into complete remission after receiving the investigational therapy (called CTL019), and 78 percent of the patients were alive six months after treatment. The longest remission among the patients has lasted almost three years.

The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants. Their cancers were so aggressive they had no treatment options left, said the studys senior author, Stephan Grupp, MD, PhD, at the Children's Hospital of Philadelphia. The durable responses we have observed with CTL019 therapy are unprecedented.

The ongoing study is being conducted by researchers at the Childrens Hospital of Philadelphia and the Hospital of the University of Pennsylvania (Penn). The CAR trial program enrolling children with leukemia is also expanding to nine other pediatric centers.

The experimental CAR therapy received FDAs breakthrough designation in July for the treatment of relapsed and refractory adult and pediatric ALL. The novel treatment was pioneered by Penn researchers and then supported by Novartis. Penn entered an exclusive global research and licensing agreement with Novartis in 2012 to develop and commercialize personalized CAR T-cell therapies for cancers.

"This represents a really powerful therapy for ALL," Penn oncologist David Porter says. "We've treated enough patients to confirm that. It's time to start multi-center trials."

A CAR is a genetically engineered marker protein that is grafted onto T cells, which are part of the immune system. The CAR activates the T cell to attack tumor cells that express specific markers; in this case, the target is a protein called CD19.

The treatment procedure involves removing patients' T cells via an apheresis process and then genetically reprogramming them to hunt tumor cells. When injected back into patients bodies, these new hunter cells multiply and attack tumor cells expressing CD19. The hunter cells can grow, creating 10,000+ new cells in the body for each single engineered cell injected into the patients.

Original post:
University Of Pennsylvania's T-Cell Therapy Shows Promising Results

Spinal Cord Injury, Lenny Larsen | Stem Cell + Epidural Stimulation Treatment Testimonial – Video

By Stem Cell Treatment


Spinal Cord Injury, Lenny Larsen | Stem Cell + Epidural Stimulation Treatment Testimonial
Only the 2nd patient to receive the revolutionary epidural stimulation + stem cell treatment for spinal cord injury, Lenny was able to breathe on his own for the first time since his tragic...

By: Beike Biotech

Read more:
Spinal Cord Injury, Lenny Larsen | Stem Cell + Epidural Stimulation Treatment Testimonial - Video

More than 900 Physicians Converge on Buenos Aires for Global Stem Cells Groups First International Symposium on Stem …

By Stem Cell Treatment

MIAMI (PRWEB) October 22, 2014

More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.

The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the worlds most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.

An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:

Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.

Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.

Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cells ability to secrete more trophic factors.

According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.

We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing, Novas says. We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physicians office and I believe we achieved our goals with this symposium.

Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.

Read the original post:
More than 900 Physicians Converge on Buenos Aires for Global Stem Cells Groups First International Symposium on Stem ...

Maritza Novas, R.N., M.S.N and Alfredo Hoyos, M.D. to Speak at the EuroMedicom Aesthetic & Anti-Aging Medicine World …

By Stem Cell Medicine

Miami, FL (PRWEB) October 21, 2014

Global Stem Cells Group has announced that Alfredo Hoyos, M.D. and Maritza Novas, R.N., M.S.N. will be speaking at the EuroMedicom First AMWC Latin America Aesthetic & Anti-aging Medicine World Congress in Medellin, Colombia, Nov. 27, 28 and 29, 2014.

The World Congress Colombia event is organized in cooperation with the International Scientific Board of the AMWC Monaco event, the largest international event in the field of aesthetic and anti-aging medicine. The goal of the event is to showcase the AMWCs commitment to innovation, expertise and excellence in aesthetic and anti-aging medicine, and to share a wealth of experience and teaching skills with attendees from around the world.

In addition to keeping up with worldwide practices, the Medellin conference is designed to contribute to enhancing practitioners skills through advanced academic and clinical sessions, as well as lectures presented by prominent experts in the field like Hoyos and Novas.

Novas and Hoyos will discuss the latest advancements in stem cell medicine for cosmetic and anti-aging applications. Hoyos, founder of Stem Lab, Global Stem Cells Group's new representative in Colombia, will also discuss plans to hold a symposium on stem cell and regenerative medicine in Bogota in Feb., 2014.

Novas is a lead trainer and part of the research and development team for Stem Cell Training, a Global Stem Cells Group subsidiary. Hoyos, a prominent Colombian plastic surgeon, is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques. Hoyos will also be promoting the new collaboration between Global Stem Cells Group and his Colombia-based Stem Lab biotechnology company, which develops stem cell techniques for regenerative medicine treatments.

Hoyos serves Global Stem Cells Group and its subsidiary Regenestem as exclusive representative for the Colombian territory. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Regenestem, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket. Five dates are planned for training and physician certification under the Global Stem Cells Group brand in Colombia during 2015.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

See the original post:
Maritza Novas, R.N., M.S.N and Alfredo Hoyos, M.D. to Speak at the EuroMedicom Aesthetic & Anti-Aging Medicine World ...

→←